Live Breaking News & Updates on Riple Antigen Oral Vaccine

Premas Biotech announced today that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain. ....

Premas Biotech , Oravax Medical , Riple Antigen Oral Vaccine , Omicron Variant , Vaccine Candidate , Joint Venture , Ars Cov 2 , Oramed Pharmaceuticals , Mymd Pharmaceuticals , Covid 19 , Prabuddha Kundu , Riple Antigen Vaccine , Nupur Mehrotra , Dovel Technologies , Infectious Diseases , Metabolic Disorders , C Qwence , D Crypt ,